Fibrin stabilization (factor XIII), fibrin structure and thrombosis

被引：35
作者：
Bereczky, Z
Katona, É
Muszbek, L
机构：
[1] Univ Debrecen, Med & Hlth Sci Ctr, Clin Res Ctr, Hungarian Acad Sci, H-4012 Debrecen, Hungary
[2] Univ Debrecen, Med & Hlth Sci Ctr, Thrombosis Res Grp, Hungarian Acad Sci, H-4012 Debrecen, Hungary
来源：
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS | 2003年 / 33卷 / 5-6期
关键词：
factor XIII; factor XIII-A Val34Leu polymorphism; fibrinolysis; thrombosis;
D O I：
10.1159/000083841
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Factor XIII (FXIII) is a zymogen that is converted into an active transglutaminase (FXIIIa) by the concerted action of thrombin and Ca2+. Its main task is to crosslink alpha-, and gamma-chains of fibrin and alpha2-plasmin inhibitor to fibrin. By this way FXlIIa strengthens fibrin and protects it from the prompt elimination by fibrinolytic system. The changes of FXIII level in thrombotic diseases are hardly explored and there are contradictory results concerning the protective effect of Val34Leu polymorphism against arterial or venous thrombosis. The results suggest that the thrombo-protective effect of Leu34 allele prevails only in certain genetic and/or environmental constellations. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码：430 / 437
页数：8
相关论文
共 108 条
[1]   CHARACTERIZATION OF FACTOR-XIII CONTAINING-MACROPHAGES IN LYMPH-NODES WITH HODGKINS-DISEASE [J].
ADANY, R ;
NEMES, Z ;
MUSZBEK, L .
BRITISH JOURNAL OF CANCER, 1987, 55 (04) :421-426
[2]  
ADANY R, 1988, THROMB HAEMOSTASIS, V60, P293
[3]   Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) study [J].
Aleksic, N ;
Ahn, C ;
Wang, YW ;
Juneja, H ;
Folsom, AR ;
Boerwinkle, E ;
Wu, KK .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (02) :348-352
[4]  
Alhenc-Gelas M, 2000, THROMB HAEMOSTASIS, V84, P1117
[5]   REDUCTION OF COAGULATION FACTOR-XIII CONCENTRATION IN PATIENTS WITH MYOCARDIAL-INFARCTION, CEREBRAL INFARCTION, AND OTHER THROMBOEMBOLIC DISORDERS [J].
ALKJAERSIG, N ;
FLETCHER, AP ;
LEWIS, M ;
ITTYERAH, R .
THROMBOSIS AND HAEMOSTASIS, 1977, 38 (04) :863-873
[6]   Factor XIII deficiency [J].
Anwar, R ;
Miloszewski, KJA .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (03) :468-484
[7]   INHIBITORS OF THE FIBRINOLYTIC ENZYME-SYSTEM [J].
AOKI, N ;
HARPEL, PC .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1984, 10 (01) :24-41
[8]   The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure [J].
Ariens, RAS ;
Philippou, H ;
Nagaswami, C ;
Weisel, JW ;
Lane, DA ;
Grant, PJ .
BLOOD, 2000, 96 (03) :988-995
[9]  
*ATHR THROMB VASC, 2003, CIRCULATION, V107, P1117
[10]   Ethnic heterogeneity of the factor XIII Val34Leu polymorphism [J].
Attié-Castro, FA ;
Zago, MA ;
Lavinha, J ;
Elion, J ;
Rodriguez-Delfin, L ;
Guerreiro, JF ;
Franco, RF .
THROMBOSIS AND HAEMOSTASIS, 2000, 84 (04) :601-603
12345678910